Chagas disease is a vector-borne zoonotic protozoan disease caused by Trypanosoma cruzi (T. cruzi) that disproportionately affects poor people throughout Latin America. 1, 2 It was first described by Carlos Chagas in Brazil in 1908 and first recognized in Mexico in the 1940s. 3 In the Americas, Chagas disease is an important neglected tropical disease in which the burden is greatest among the poorest and most marginalized communities. 1, 2, 4, 5 Chagas disease results in an estimated loss of 670,000 disability-adjusted life years annually throughout Latin America. 2 The primary mode of transmission of the parasite to humans occurs via contact with feces of an infected triatomine insect (Order Hemiptera, Family Reduviidae, Subfamily Triatominae) that typically occurs when the triatomine insect or "kissing bug" takes a blood meal from a host and defecates near the wound. Other modes of transmission include bloodborne, organ transplant, congenital, and oral (foodborne). [6] [7] [8] 
CHAGAS DISEASE BACKGROUND

Pathophysiology
In humans, Chagas disease progresses through acute and chronic phases. Acute cases are difficult to clinically detect because most individuals experience no or generalized symptoms in this stage. 9, 10 Then, 4 to 8 weeks later, infected individuals enter the chronic phase where T. cruzi moves into the tissues. Many individuals remain in the indeterminate form of chronic-stage disease. 11 However, after a 15-to 20-year latency with indeterminate chronic Chagas disease with no clinical symptoms, approximately 30% of infected individuals develop cardiac or gastrointestinal complications. 11, 12 Symptomatic chronic-stage patients often present with severe cardiomyopathy resulting in high morbidity and mortality. 12 Chagas disease is an important cause of heart failure in Mexico and is the leading cause of cardiac lesions in young adults throughout endemic areas of Latin America. 7, 12, 13 In São Paulo state in Brazil, 8% of heart failure deaths were attributable to chronic Chagas disease, 13 and in southern parts of Mexico, dilated cardiomyopathy is most commonly caused by Chagas disease. 14, 15 Surveillance Given the severe health consequences and high disease burden, concerted efforts to improve surveillance efforts, which are vital for control and prevention programs, are being made throughout Central and South America, with goals to (1) eliminate vector populations and transmission via blood transfusion, (2) improve housing, and (3) develop disease-monitoring systems. 12, 16, 17 Initiatives in Central and South America have successfully decreased disease burden via vector control and active case detection through blood screening.
The Southern Cone Initiative began in 1991 as a collaborative Chagas disease control effort among the southernmost countries in South America. 12, 17 Following this collaboration, the Initiative of the Andean Countries and the Initiative of Central America and Mexico began in 1997. In Mexico, a great deal of work remains to help control Chagas disease vectors. 16 The Initiative of the Amazon Countries began in 2002. 12, 16 These initiatives have been successful, reducing incidence from 700,000 cases per year in 1991 to 41, 200 cases per year in 2006. From 1991 to 2001, the number of disability-adjusted life years decreased from 2.7 million in 1991 to 586,000 in 2001 in Latin America. 17, 18 Chagas disease surveillance in Mexico Prior to passing legislation mandating serologic screening of blood donors in 2000 and the convening of the Mexican Initiative for Surveillance and Control of Chagas Disease with the purpose of evaluating potential control measures in 2002, 19, 20 Chagas disease was largely neglected in Mexico. 21 Case data became publicly available in 2003. 22 Currently, the entire health sector reports cases and deaths to the National Center for the Prevention and Control of Diseases, with most cases reported through the Secretary of Health. 23 The majority of cases are identified through blood donor screenings, and others are identified by diagnosing physicians. 24 Reports ultimately reach the Single Automated System for Epidemiological Surveillance. 22 Boletín Epidemiológico publishes all results. 25 Despite the implementation of surveillance measures, however, Chagas disease continues to be understudied and poorly controlled in Mexico. 19, 21, 25, 26 One problem with the current reporting system is that it does not distinguish among acute, indeterminate, and chronic cases; as such, reporting methods cannot determine whether or not reported cases are incident cases. 19 Blood bank testing Mandatory blood donor screening was initiated through legislation, but resource shortages led to only 30% of samples being processed through initial screening and follow-up testing required for confirmation. 21 Blood donor screening methods detect anti-T. cruzi antibodies by hemagluttination inhibition test, indirect immunofluorescence assay, enzyme-linked immunosorbent assay, and Western blot analysis. 3, 27 The range of sensitivities and specificities of these tests may lead to inconsistencies among testing facili-ties and produce results that alter our perception of the disease burden.
Case confirmation
In Mexico, a confirmed case is defined as a patient presenting symptoms of acute infection and presence of parasite demonstrated on a thick blood smear; through hemoconcentration of the blood sample; by culturing on Novy-MacNeal-Nicolle modified medium; through positive serology to at least two tests including indirect immunofluorescence assay, hemagluttination inhibition test, and enzyme-linked immunosorbent assay; or by any technique deemed appropriate by the testing authority. 24 Because of these varied and vague (i.e., tests deemed appropriate by testing facilities) testing techniques, there is a great potential for misclassification of cases.
PURPOSE OF EVALUATION
The level of reporting in Mexico differs among states, possibly associated with a deficiency of physician awareness and scarcity of resources, including availability of testing. Inconsistencies in surveillance prohibit the development of a comprehensive and accurate picture of the epidemiology of Chagas disease in Mexico, and it continues to be poorly understood. 19, 25 Assessments of the officially reported burden and distribution of Chagas disease in Mexico have not been previously reported. 28 To evaluate the current level of discontinuity between surveillance data and data from other sources, we used data from the Mexican Ministry of Health to describe the distribution of reported Chagas disease over time in Mexico and compare it with estimates from the literature. We discuss how problems with surveillance data misrepresent the burden of this devastating disease in Mexico. Finally, we discuss current improvements to the surveillance system and make suggestions to further increase the validity of surveillance data to study Chagas disease in Mexico.
METHODS
Data
Data were acquired from the Ministry of Health for positive cases, along with Chagas disease-related deaths. 22 While the Ministry of Health asserts that reported cases are acute cases, 29 it is likely that many people with reported cases of Chagas disease are in the chronic phase. Reported cases were confirmed through any of the aforementioned methods, including presentation with symptoms to a physician, presence of parasite on a blood smear, or positive serology.
Analysis
Available case data were from 1995 to 2013. We chose the 1998-2010 time span for these analyses because we wanted to analyze data beginning around the time that mandatory serologic screening of blood donors was offically implemented. 19, 20 Available mortality data spanned 1979-2010, and we used all years because no obvious changes to mortality reporting occurred. In the dataset, case and mortality data were stratified by age group and sex. Although stratifications were inconsistent across the dataset, we used them where available.
We calculated the proportion of reported cases and deaths by age group and sex, and compared these proportions using a chi-squared test of difference in proportions to determine significant differences of reported cases and mortality between age groups and sex. We mapped rates for three relatively equal time periods, 1998-2003, 2004-2008, and 2009-2013, to show reporting changes in case distribution over time. We grouped data using Jenks natural breaks, a method in which data groups are divided where large divisions naturally occur in the data. 30 We performed spatial visualization using ArcGIS ® ArcMap release 10. 31 Chi-squared analysis was performed using Stata ® version 12.1. 32 To determine statistical significance, we set the alpha level at 0.05.
RESULTS
Incidence and mortality
In total, 6,494 cases of Chagas disease were reported officially from 1995 to 2013, and 496 deaths from Chagas disease were reported from 1982 to 2010. Most reported cases were among adults aged 25-44 years (n53,069, 47.3%) followed by those aged 45-64 years (n51,430, 22.0%). The reported mortality was greatest among individuals aged $45 years (n5423, 85.2%). Deaths occurred fairly equally between males (n5262, 52.8%) and females (n5234, 47.2%, p50.259) (Table) .
Temporal distribution
Since implementation of mandatory serological screening of blood donors, the rate of reported Chagas disease increased from 0.02 per 100,000 population in 1998 to 0.73 per 100,000 population in 2011, with a slight drop to 0.64 per 100,000 population in 2013 ( Figure 1a ). An increase in mortality rate occurred from 0.004 per 100,000 population in 1979 to 0.034 per 100,000 population in 2009, with a drop to 0.018 per 100,000 population in 2010 ( Figure 1b ). (Years shown for mortality data differ from the Table to Figure  1 because no age or sex stratifications were available from 1979 to 1981.)
The rate of officially reported disease increased over time, and the geographic distribution changed. During 1998-2003, the reported rate was very low; only a few states in south-central Mexico had a rate higher than 1.0 cases per 100,000 population. During 2004-2008, an increase in reported rate occurred, with a notable increase in rates among southern states. During 2009-2013, the rate increased further, although to a lesser degree than during 2004-2008, and increased rates were reported among areas previously considered free of Chagas disease (Figure 2 ). Across all years, southern states showed higher reporting.
DISCUSSION
We demonstrated that the officially reported cases and mortality of Chagas disease in Mexico have changed over space and time and described how changes in the surveillance of this disease have led to better convergence of what is reported nationally and what is reported in the literature. Most cases were reported in individuals aged 25-44 years, followed by those aged 45-64 years, while most officially reported deaths attributed to Chagas disease occurred in individuals aged $45 years. This age trend is expected for case detection, as seropositivity increases with age. 20 Because T. cruzi infection is generally lifelong, more cases are likely to be identified in adult populations. Older age groups are also expected to have greater mortality burden due to the heart tissue damage that T. cruzi inflicts over time. 33 Likely because of better reporting by southern states, our results indicate that cases have been reported more frequently in southern states than in northern states. However, it is likely that all states are endemic for Chagas disease, as competent vectors and reservoirs are geographically widespread, other transmission modes are possible, and, in the literature, seroprevalence has been reported in all states, with the lowest rate being 0.5%. 34 The distribution of vectors and, thus, T. cruzi, may also expand with climate change as increasing temperatures create suitable environments for vector populations. 35 Increasing rates of disease and changes in distribution probably indicate greater official recognition of Chagas disease in Mexico and likely are due to increasing awareness, greater research focus, and mandatory serological blood donor screening. These changes probably do not reflect actual changes in the distribution or incidence of the disease. Continually increasing awareness among health units may help further reduce discrepancies and provide a more accurate picture of Chagas disease epidemiology.
Researchers have long recognized that using officially reported national surveillance data leads to a large underestimation of Chagas disease burden in Mexico. Fewer than 900 incident cases and 40 deaths are reported officially every year. Many incidence estimates in the literature have been based on prevalence and other factors. 36 The variability in these estimates comes from such factors as whether estimates are extrapolated from officially reported data, from wider Latin American estimates, or from studies conducted by nongovernmental research groups. The federally recognized national seroprevalence rate calculated from a 1980s national serological survey was estimated at 1.6% of the population, ranging by state from 0.2% to 2.8%. 20, 37 Using data from 546 blood banks, Tapia-Conyer estimated the Chagas disease prevalence rate to be 0.5%. 29 Ramsey et al. noted that national prevalence may be as high as 2.0% (range: 0.5%-2.0%), also from blood bank data. 26, 36 These prevalence estimates translate to approximately 561,683 prevalent cases at the low end (0.5%) to 2,246,731 prevalent cases at the high end (2.0%) based on the 2010 census population. 38 Estimates based on smaller observational studies throughout Mexico indicate that close to 69,000 new cases and 25,000 deaths each year are due to Chagas disease. 20, 26, 28, [36] [37] [38] [39] Other estimates are based on regional populations and certain subpopulations. For example, the prevalence of Chagas disease among pregnant women was 4.4% in Oaxaca, 12.0% in Jalisco, and 4.1% in Mexico City. 40 In a seroprevalence study conducted in Nuevo Leon, which is considered to be non-endemic, 2.8% T. cruzi seropositivity was found among study participants. These participants also included migrants from Coahuila (3.1% seropositivitiy) and Tamaulipas (4.0% seropositivity), both also considered non-endemic states. 41 A cross-sectional seroprevalence study in the Tejupilco area of the state of Mexico (thought to be free of T. cruzi transmission because of altitude) found T. cruzi-specific immunoglobulin G and immunoglobulin M antibodies in 7.1% of participants. 42 Some inherent limitations exist in using prevalence data to determine disease burden. Certain prevalence data may not accurately represent the current burden of Chagas disease. Societal changes, such as in housing conditions, likely have occurred and possibly have affected transmission dynamics and the distribution of disease. Additionally, some prevalence estimates may originate from studies conducted in high-risk areas, possibly resulting in an overestimation of general prevalence.
Limitations
This study was subject to several limitations. The greatest limitation was, as long recognized by researchers, reported surveillance data for Chagas disease are difficult to interpret, and thus, cannot accurately estimate disease burden. Possible reasons for underreporting include missed diagnoses among acute cases, nondetection of indeterminate and chronic cases, and non-uniform surveillance. Because Chagas disease is not traditionally considered endemic in northern states, 28 it is likely that health units in these states do not consider Chagas disease a problem for their population, which may lead to limited testing. Additionally, underreporting is an issue because Chagas disease has few acutely symptomatic cases, and it is difficult to detect trypomastigote parasite forms in blood. 43 
CONCLUSION
Over time, the surveillance system is capturing more cases since implementation of mandatory serologic screening of blood donors, so we are gaining a better understanding of the epidemiology of Chagas disease in Mexico. However, better case reporting and increased awareness in non-endemic states are still needed. Recommendations include ensuring proper screening for all blood donations, developing sentinel sites such as larger regional hospitals to screen children, increasing physician awareness of Chagas disease throughout the country, and heightening awareness that adults presenting with cardiomyopathy may have Chagas disease. Chagas disease continues to inflict a significant burden on affected populations, and its story in Mexico reflects the challenges to passive disease surveillance. Mexico has implemented mandatory blood donor screening and standardized surveillance measures. Great care must be made in interpreting surveillance data to determine whether or not these control programs are effective. Monitoring changes such as hospitals and facilities reporting, as well as periodic reviews of testing protocols and other evaluation systems, must be in place for the data to be useful. Improvements are leading to better disease estimates, but they do make it more difficult to assess temporal trends. Greater participation of health units and hospitals in standardized national and state-level surveillance measures established to characterize acute, indeterminate, and chronic cases as well as deaths will continue to improve our understanding of the epidemiology of Chagas disease in Mexico. Understanding the epidemiology of Chagas disease is essential for effective, targeted control and prevention measures to lessen its burden in Mexico, and evidence-based policy changes are critically needed for improvement.
